Animal models are the most commonly used model that helps to improve the understanding of the genetic alterations that occur in humans during the carcinogenic environment. Furthermore, these models play a pivotal role in the illustration of tumorigenesis and therapeutic strategies. With the advancement in molecular biology, the use of nanomedicine for breast cancer treatment has progressed, and more is expected to be done in the future pretrial and clinical models to achieve more success. The biocompatibility of 3D printing platforms has been reported to be adequate in terms of cell viability; however, the effects on gene expression and functional aspects have received less attention. Various mechanical and visual disruptions to cells are involved depending on the type of bioprinter employed. Additional research into the mechanical and optical effects of the bioprinting process will provide more insight into the 3D printing technique' biocompatibility. To investigate the microenvironment of breast tumours and 3D bioprinting methods have also been studied. Modalities for bioprinting include extrusion-based (EBB) printing, droplet-based (DBB) printing and laser-based bioprinting. Different research has indicated that new developments of novel cancer modelling have emerged with 3D bioprinting technology. Those studies need to be properly explained and analyses in a Broadway in this review and to help in the progress of cancer research.